CONMED (CNMD) – Research Analysts’ Weekly Ratings Changes
by Kim Johansen · The Markets DailyA number of firms have modified their ratings and price targets on shares of CONMED (NYSE: CNMD) recently:
- 7/20/2026 – CONMED was upgraded by Wall Street Zen from “hold” to “buy”.
- 7/13/2026 – CONMED had its “hold” rating reaffirmed by Needham & Company LLC.
- 7/13/2026 – CONMED was given a new $39.00 price target by Wells Fargo & Company.
- 7/13/2026 – CONMED was downgraded by Zacks Research from “hold” to “strong sell”.
- 7/12/2026 – CONMED was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/8/2026 – CONMED is now covered by BMO Capital Markets. They set a “market perform” rating and a $36.00 price target on the stock.
- 7/8/2026 – CONMED was upgraded by BMO Capital Markets to “hold”.
- 6/29/2026 – CONMED had its “underperform” rating reaffirmed by Bank of America Corporation. They now have a $40.00 price target on the stock.
- 6/4/2026 – CONMED had its “sell (d)” rating reaffirmed by Weiss Ratings.
CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.
CONMED operates two principal segments: Orthopedics, and Visualization & Energy.